June 10, 2022 10:34 AM EDTUpdated June 13, 02:02 PM
News Briefing

Ever­est Med­i­cines reach­es its first peak in Chi­na with Trodelvy nod; Cy­cle­ri­on touts da­ta in small study

Kyle LaHucik

Senior Reporter

While strug­gling at home to prove sig­nif­i­cant dif­fer­ence in over­all sur­vival com­pared to stan­dard of care, Gilead’s Trodelvy is head­ed to Chi­na through …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times